Immuneering (IMRX) vs SIGA Technologies (SIGA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immuneering (IMRX) has outperformed SIGA Technologies (SIGA) over the past year, losing 36.8% versus a loss of 61.4%. Over five years, SIGA leads with a -54.1% price change compared with -84.5% for IMRX. Immuneering is the larger company by market cap ($241.6 million vs $237.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMRX | SIGA |
|---|---|---|
| Share price | $3.74 | $3.31 |
| Market cap | $241.64M | $237.82M |
| 1-day change | -3.24% | +1.53% |
| YTD return | -41.34% | -46.64% |
| 1-year return | -36.82% | -61.37% |
| 5-year return | -84.47% | -54.15% |
| Forward P/E | — | 3.06 |
| EPS (TTM) | $-0.93 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.48 | $8.55 |
| 52-week low | $3.60 | $2.83 |
| Distance from 52-week high | -55.96% | -61.29% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +359.71% | — |
| Average volume | 694.54K | 726.50K |
| Shares outstanding | 64.70M | 71.85M |
| Employees | 57 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMRX has outperformed SIGA by 24.5 percentage points over the past year.
About Immuneering
IMRX stock →Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About SIGA Technologies
SIGA stock →SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
IMRX vs SIGA FAQ
Which is bigger, Immuneering or SIGA Technologies?
Immuneering (IMRX) is larger, with a market capitalization of $241.64M compared with $237.82M for SIGA Technologies (SIGA).
Which stock has performed better over the past year, IMRX or SIGA?
IMRX returned -36.82% over the past 12 months, compared with -61.37% for SIGA (price return, excluding dividends). Past performance does not predict future results.
Are Immuneering and SIGA Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.